Advertisement

Tumor Biology

, Volume 36, Issue 5, pp 3389–3397 | Cite as

The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients

  • Shaodong Hong
  • Ting Zhou
  • Wenfeng Fang
  • Cong Xue
  • Zhihuang Hu
  • Tao Qin
  • Yanna Tang
  • Yue Chen
  • Yuxiang Ma
  • Yunpeng Yang
  • Xue Hou
  • Yan Huang
  • Hongyun Zhao
  • Yuanyuan Zhao
  • Li Zhang
Research Article

Abstract

Recent studies have shown the prognostic nutritional index (PNI) had prognostic value in some solid tumors. However, no studies have examined its prognostic role in small-cell lung cancer (SCLC) patients. In this retrospective study, 724 consecutive SCLC patients were included between 2006 and 2013. Demographic, clinical, and laboratory data were collected. The PNI was calculated as 10 × serum albumin value (g/dl) + 0.005 × peripheral lymphocyte count (per mm3). Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. The optimal cut-off value of PNI for OS stratification was determined to be 52.48. A total of 464 and 260 patients were assigned to low and high PNI groups, respectively. Compared with low PNI, high PNI was associated with older age, advanced stage, and elevated lactate dehydrogenase (LDH). Median overall survival (OS) was worse in the low PNI group (low vs high, 15.90 vs 25.27 months; HR, 0.62; p < 0.001). In multivariate analysis, stage, performance status, LDH, and PNI were independent prognostic factors for OS. Subgroup analysis showed PNI was generally a significant prognostic factor in different clinical situations. The assessment of PNI could assist the identification of patients with poor prognosis and be a hierarchical factor in the future SCLC clinical trials.

Keywords

Small cell Lung cancer Albumin Lymphocyte Prognosis 

Notes

Acknowledgments

We thank all the patients who entered this study. This work was supported by the Wu Jieping Medical Foundation Project (Grant No. 08-JC-003), the Innovative drug R&D center based on real-time high-throughput cell-based screening platform and large capacity compound library (Grant No. 2013ZX09401003-002), the National Natural Science Funds of China (Grant No. 81372502), and the National High Technology Research and Development Program of China (Grant No. 2012AA02A502). All the grand supporters have no roles in study design, data collection and analysis, and manuscript preparation.

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi: 10.3322/caac.21208.CrossRefPubMedGoogle Scholar
  2. 2.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. doi: 10.1056/NEJMra0802714.CrossRefPubMedGoogle Scholar
  3. 3.
    Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20–37. doi: 10.1634/theoncologist.12-1-20.CrossRefPubMedGoogle Scholar
  4. 4.
    Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810–6. doi: 10.1093/annonc/mdq036.CrossRefPubMedGoogle Scholar
  5. 5.
    Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014;15(1):106–13. doi: 10.1016/S1470-2045(13)70511-4.CrossRefPubMedGoogle Scholar
  6. 6.
    Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e400S–19. doi: 10.1378/chest. 12-2363.CrossRefPubMedGoogle Scholar
  7. 7.
    F JB, Costa AF. Small cell lung cancer--state of the art and future perspectives. Rev Port Pneumol. 2007;13(4):587–604Google Scholar
  8. 8.
    Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol. 1988;15(3):278–99.PubMedGoogle Scholar
  9. 9.
    Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990;61(4):597–604.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Stokkel MP, van Eck-Smit BL, Zwinderman AH, Willems LN, Pauwels EK. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma. J Cancer Res Clin Oncol. 1998;124(3–4):215–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89(3):523–33.CrossRefPubMedGoogle Scholar
  12. 12.
    Jorgensen LG, Osterlind K, Genolla J, Gomm SA, Hernandez JR, Johnson PW, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer. 1996;74(3):463–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yang X, Wang D, Yang Z, Qing Y, Zhang Z, Wang G, et al. CEA is an independent prognostic indicator that is associated with reduced survival and liver metastases in SCLC. Cell Biochem Biophys. 2011;59(2):113–9. doi: 10.1007/s12013-010-9121-0.CrossRefPubMedGoogle Scholar
  14. 14.
    Maestu I, Pastor M, Gomez-Codina J, Aparicio J, Oltra A, Herranz C, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol. 1997;8(6):547–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Laurie SA, Ding K, Whitehead M, Feld R, Murray N, Shepherd FA, et al. The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2007;18(6):1051–5. doi: 10.1093/annonc/mdm077.CrossRefPubMedGoogle Scholar
  16. 16.
    Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkaishi Zasshi. 1984;85(9):1001–5.Google Scholar
  17. 17.
    Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185. doi: 10.1155/2014/149185.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ikeya T, Shibutani M, Maeda K, Sugano K, Nagahara H, Ohtani H, et al. Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer. J Cancer Res Clin Oncol. 2014. doi: 10.1007/s00432-014-1799-8.PubMedGoogle Scholar
  19. 19.
    Migita K, Takayama T, Saeki K, Matsumoto S, Wakatsuki K, Enomoto K, et al. The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage. Ann Surg Oncol. 2013;20(8):2647–54. doi: 10.1245/s10434-013-2926-5.CrossRefPubMedGoogle Scholar
  20. 20.
    Yao ZH, Tian GY, Wan YY, Kang YM, Guo HS, Liu QH, et al. Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma. J Cancer Res Clin Oncol. 2013;139(12):2117–23. doi: 10.1007/s00432-013-1523-0.CrossRefPubMedGoogle Scholar
  21. 21.
    Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106(8):1439–45. doi: 10.1038/bjc.2012.92.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29(5):3092–100. doi: 10.1007/s12032-012-0226-8.CrossRefPubMedGoogle Scholar
  23. 23.
    van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–55. doi: 10.1016/S0140-6736(11)60165-7.CrossRefPubMedGoogle Scholar
  24. 24.
    Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862. doi: 10.1371/journal.pone.0051862.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Eatrides J, Thompson Z, Lee JH, Bello C, Dalia S. Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma. Ann Hematol. 2014. doi: 10.1007/s00277-014-2150-9.PubMedGoogle Scholar
  26. 26.
    Biswas B, Rastogi S, Khan SA, Shukla NK, Deo SV, Agarwala S, et al. Hypoalbuminaemia is an independent predictor of poor outcome in metastatic ewing’s sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol. Clin Oncol (R Coll Radiol). 2014. doi: 10.1016/j.clon.2014.05.006.Google Scholar
  27. 27.
    Du XJ, Tang LL, Mao YP, Sun Y, Zeng MS, Kang TB, et al. The pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinoma. PLoS One. 2014;9(4):e94473. doi: 10.1371/journal.pone.0094473.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Li G, Gao J, Liu ZG, Tao YL, Xu BQ, Tu ZW, et al. Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: long-term outcomes of 512 patients from a single institution. Head Neck. 2014;36(5):660–6. doi: 10.1002/hed.23357.CrossRefPubMedGoogle Scholar
  29. 29.
    Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev. 2014;40(6):685–91. doi: 10.1016/j.ctrv.2013.11.007.CrossRefPubMedGoogle Scholar
  30. 30.
    McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257–62. doi: 10.1017/S0029665108007131.CrossRefPubMedGoogle Scholar
  31. 31.
    Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi: 10.1093/jnci/dju124.CrossRefPubMedGoogle Scholar
  32. 32.
    Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–12. doi: 10.1158/1055-9965.EPI-14-0146.CrossRefPubMedGoogle Scholar
  33. 33.
    McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40. doi: 10.1016/j.ctrv.2012.08.003.CrossRefPubMedGoogle Scholar
  34. 34.
    Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology. 1988;8(2):385–401.CrossRefPubMedGoogle Scholar
  35. 35.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. doi: 10.1038/nature07205.CrossRefPubMedGoogle Scholar
  36. 36.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. doi: 10.1038/nature01322.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ceze N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 2011;68(5):1305–13. doi: 10.1007/s00280-011-1610-3.CrossRefPubMedGoogle Scholar
  38. 38.
    Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–91. doi: 10.1158/0008-5472.CAN-08-3845.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res. 2006;12(24):7492–7. doi: 10.1158/1078-0432.CCR-06-0023.CrossRefPubMedGoogle Scholar
  40. 40.
    Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer. 2002;87(3):277–80. doi: 10.1038/sj.bjc.6600448.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Paccagnella A, Morassutti I, Rosti G. Nutritional intervention for improving treatment tolerance in cancer patients. Curr Opin Oncol. 2011;23(4):322–30. doi: 10.1097/CCO.0b013e3283479c66.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Shaodong Hong
    • 1
    • 2
    • 3
  • Ting Zhou
    • 1
    • 2
    • 3
  • Wenfeng Fang
    • 1
    • 2
    • 3
  • Cong Xue
    • 1
    • 2
    • 3
  • Zhihuang Hu
    • 1
    • 2
    • 3
  • Tao Qin
    • 1
    • 2
    • 3
  • Yanna Tang
    • 4
  • Yue Chen
    • 5
  • Yuxiang Ma
    • 1
    • 2
    • 3
  • Yunpeng Yang
    • 1
    • 2
    • 3
  • Xue Hou
    • 1
    • 2
    • 3
  • Yan Huang
    • 1
    • 2
    • 3
  • Hongyun Zhao
    • 1
    • 2
    • 3
  • Yuanyuan Zhao
    • 1
    • 2
    • 3
  • Li Zhang
    • 1
    • 2
    • 3
  1. 1.Department of Medical OncologySun Yat-Sen University Cancer CenterGuangzhouChina
  2. 2.State Key Laboratory of Oncology in South ChinaGuangzhouChina
  3. 3.Collaborative Innovation Center for Cancer MedicineGuangzhouChina
  4. 4.Department of OncologyThe Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhaiChina
  5. 5.Medical SchoolUniversity of South ChinaHengyangChina

Personalised recommendations